ARTICLE | Company News
Genomic Vision and AstraZeneca collaborate to screen WEE1 inhibitors
June 9, 2017 8:18 PM UTC
AstraZeneca plc (LSE:AZN; NYSE:AZN) will use the FiberVision DNA molecular combing technology from Genomic Vision S.A. (Euronext:GV) to evaluate the impact of WEE1 tyrosine kinase (WEE1) inhibitors ...
BCIQ Target Profiles